Changes in Beneficial Ownership · 4
VERTEX PHARMACEUTICALS INC / MA
VRTXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1783368787.xml
Filing details
- Report period
- 2026-07-01
- Issuer
- VERTEX PHARMACEUTICALS INC / MA
- Issuer CIK
- 0000875320
- Trading symbol
- VRTX
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Liu Joy
- Reporting owner CIK
- 0001847529
- Relationship
- Officer
- Officer title
- EVP and Chief Legal Officer
- Address
- C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-07-01 | S · Form 4[F1] | 828 | D | 502.71 | 19,131 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.↩ 1
Signature 1
- Signed
- /s/ Christiana Stevenson, Attorney-in-Fact
- Date
- 2026-07-06
Company context
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain and acromegaly, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, congenital adrenal hyperplasia, ACTH-dependent Cushing's syndrome, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1.
Current securities
Recent company filings
- 10-Q filingNov 3, 2026
- Results of Operations and Financial ConditionNov 2, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 20, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 1, 2026
- 4 filingAug 31, 2026